Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

OKYO Pharma Limited Sponsored ADR OKYO

Healthcare  —  Biotechnology
1.38 0.00 0.00% as of 25 Sep
Market cap
$72.4M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

OKYO Pharma Limited Sponsored ADR (OKYO) Business Profile

Updated before January 2025

Company Overview

OKYO Pharma Limited Sponsored ADR (OKYO) is a biopharmaceutical company focused on the discovery and development of innovative therapies for inflammatory and ocular diseases. Founded in 2007, the company is headquartered in London, United Kingdom. OKYO is publicly traded on the NASDAQ under the ticker symbol “OKYO.” The company is led by a team of experienced professionals in the pharmaceutical and biotechnology sectors, with key leadership including Dr. Gary S. Jacob, who serves as the Chief Executive Officer. Dr. Jacob brings decades of experience in drug development and commercialization, positioning OKYO as a leader in its niche market.

Core Business Segments

OKYO operates primarily in the biopharmaceutical sector, with a focus on developing treatments for ocular and inflammatory diseases. The company’s core business segments include:

Ocular Disease Therapies

OKYO is dedicated to addressing unmet medical needs in the field of ophthalmology. Its flagship product candidate, OK-101, is a lipid-conjugated chemerin peptide designed to treat dry eye disease (DED). Dry eye disease is a chronic condition that affects millions of people worldwide, and OKYO’s innovative approach aims to provide relief by targeting inflammation and neuropathic pain associated with the condition.

Inflammatory Disease Therapies

In addition to ocular diseases, OKYO is exploring treatments for broader inflammatory conditions. The company leverages its expertise in lipid-based drug delivery systems to develop therapies that can address systemic inflammation, which is a common underlying factor in many chronic diseases.

Business Model

OKYO’s business model revolves around research and development (R&D) and strategic partnerships. The company invests heavily in preclinical and clinical trials to bring its innovative therapies to market. Revenue generation is expected to come from licensing agreements, milestone payments, and royalties from commercialized products. OKYO also collaborates with academic institutions and industry partners to accelerate the development of its drug candidates, thereby reducing costs and time-to-market.

Strategic Direction

OKYO is committed to expanding its pipeline of innovative therapies while maintaining a focus on sustainability and long-term growth. Key strategic initiatives include:

  • Advancing Clinical Trials: The company is prioritizing the progression of OK-101 through clinical trials, with the goal of obtaining regulatory approval and commercializing the product.
  • Expanding the Pipeline: OKYO aims to identify and develop additional drug candidates targeting other ocular and inflammatory diseases.
  • Sustainability Goals: The company is exploring environmentally friendly practices in its R&D and manufacturing processes to align with global sustainability standards.
  • Global Market Expansion: OKYO plans to establish a presence in key international markets, leveraging partnerships and collaborations to reach a broader patient population.

Competitive Landscape

OKYO operates in a highly competitive biopharmaceutical industry, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Allergan (a subsidiary of AbbVie): Known for its portfolio of ophthalmology products, including treatments for dry eye disease.
  • Novartis: A global pharmaceutical leader with a strong presence in the ophthalmology market.
  • Regeneron Pharmaceuticals: Offers innovative therapies for retinal diseases and other ocular conditions.
  • Smaller Biotech Firms: Companies such as Aldeyra Therapeutics and Oyster Point Pharma also focus on developing treatments for dry eye disease and other ocular conditions.

OKYO differentiates itself through its unique approach to drug development, leveraging lipid-based delivery systems and targeting both inflammation and neuropathic pain.

Risk Factors

Like any biopharmaceutical company, OKYO faces several risks that could impact its operations and financial performance:

  • Regulatory Risks: The approval process for new drugs is lengthy and uncertain, with no guarantee of success.
  • Market Dependence: The company’s reliance on a limited number of product candidates increases its vulnerability to market fluctuations and competitive pressures.
  • Supply Chain Disruptions: Global supply chain issues could delay the production and distribution of its therapies.
  • Financial Risks: As a pre-revenue company, OKYO depends on external funding to finance its operations, making it susceptible to market conditions and investor sentiment.

Recent Developments

OKYO has made significant progress in advancing its pipeline and corporate strategy:

  • OK-101 Clinical Trials: The company recently initiated Phase 2 clinical trials for OK-101, marking a critical milestone in its development.
  • Collaborations: OKYO has entered into partnerships with leading academic institutions to enhance its R&D capabilities.
  • Regulatory Filings: The company has submitted key regulatory documents to expedite the approval process for its drug candidates.
  • Global Developments: The COVID-19 pandemic highlighted the importance of addressing unmet medical needs, reinforcing OKYO’s commitment to innovation in healthcare.

Investment Considerations

Investors considering OKYO should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: OKYO’s focus on addressing unmet medical needs positions it as a potential leader in the biopharmaceutical industry.
  • Experienced Leadership: The company’s management team has a proven track record in drug development and commercialization.
  • Strategic Partnerships: Collaborations with academic and industry partners enhance OKYO’s R&D capabilities and reduce costs.

Risks

  • Pre-Revenue Status: As a company in the development stage, OKYO has yet to generate revenue, making it reliant on external funding.
  • Regulatory Uncertainty: The success of its drug candidates depends on obtaining regulatory approval, which is not guaranteed.
  • Market Competition: OKYO faces intense competition from established pharmaceutical companies and other biotech firms.

Conclusion

OKYO Pharma Limited Sponsored ADR is a promising biopharmaceutical company with a focus on developing innovative therapies for ocular and inflammatory diseases. While the company faces significant risks, its strong leadership, innovative pipeline, and strategic partnerships position it for long-term growth. As OKYO advances its clinical trials and expands its pipeline, it has the potential to make a meaningful impact in the healthcare industry and deliver value to its investors.